신경 병증 통증 치료 시장 : 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Neuropathic Pain Treatment Market was valued at USD 8.2 billion in 2024 and is estimated to grow at a CAGR of 8.3% to reach USD 18.1 billion by 2034. This robust growth trajectory is fueled by a rising burden of neuropathic pain disorders worldwide, fueled by factors such as an aging global population, lifestyle-related diseases, and a surge in chronic conditions like diabetes and cancer. As awareness about nerve-related pain and its debilitating effects increases, the demand for early diagnosis and effective treatment strategies continues to soar. The market is further propelled by evolving patient preferences, with a significant shift away from opioid-based therapies due to stringent government regulations and growing safety concerns. Advancements in drug delivery systems, biotechnology, and novel formulations have opened new doors for the treatment landscape. The availability of digital health platforms and telemedicine services is enhancing access to specialized care, particularly in underserved regions, accelerating diagnosis and timely intervention for neuropathic conditions.

The increasing prevalence of chronic pain and the urgent need for safer treatment alternatives are driving the development of next-generation therapies. Manufacturers are focusing on innovative drug pipelines that include non-opioid medications, gene therapies, monoclonal antibodies, and biosimilars designed to address both acute and chronic forms of neuropathic pain. These breakthrough therapies aim to provide targeted, long-lasting relief while minimizing side effects, representing a major leap forward in pain management.

Based on drug class, anticonvulsants continue to dominate the market and are expected to grow at a CAGR of 8.5%, reaching USD 7.8 billion by 2034. Widely prescribed medications like pregabalin, gabapentin, and carbamazepine are recognized as first-line treatments due to their high efficacy and favorable safety profiles. Their extensive use is especially notable in the treatment of diabetes-induced neuropathy, postherpetic neuralgia, and spinal cord injuries. As chronic disease incidence rises, so does the adoption of these proven medications, reinforcing their stronghold in the market.

When it comes to indications, diabetic neuropathy accounted for USD 3 billion in revenue in 2024. The escalating number of diabetic patients globally is generating sustained demand for long-term treatment solutions. Increased insurance coverage and reimbursement for neuropathic treatments are making therapies such as pregabalin and capsaicin patches more accessible to patients, improving adherence and outcomes.

The U.S. Neuropathic Pain Treatment Market alone was valued at USD 3.3 billion in 2024 and is anticipated to witness significant growth ahead. This rise is primarily due to the country's aging population and the rising prevalence of conditions like cancer, diabetes, and shingles. Federal restrictions on opioid prescriptions are also reinforcing the demand for non-opioid alternatives, encouraging a major shift in treatment dynamics.

Assertio Therapeutics, Glenmark Pharmaceuticals, Cipla, Dr. Reddy's Laboratories, Johnson & Johnson, Eli Lilly and Company, GlaxoSmithKline, Biogen, Grunenthal, Mallinckrodt Pharmaceuticals, Novartis, Pfizer, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, and Vertex Pharmaceuticals are among the leading companies shaping this dynamic landscape. These firms are actively expanding their therapeutic pipelines and forging strategic alliances with research organizations to bring novel treatments to market faster and more effectively.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of neuropathic pain disorders
    • 3.2.1.2 Advancements in drug development and novel therapies
    • 3.2.1.3 Growing geriatric population
    • 3.2.1.4 Increasing awareness towards timely treatment
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of neuropathic pain medications
    • 3.2.2.2 Side effects and risk of drug abuse
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Pipeline analysis
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Anticonvulsants
• 5.3 Antidepressants
• 5.4 Opioids
• 5.5 Capsaicinoids
• 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Diabetic neuropathy
• 6.3 Postherpetic neuralgia
• 6.4 Trigeminal neuralgia
• 6.5 Chemotherapy-induced peripheral neuropathy
• 6.6 HIV-associated neuropathy
• 6.7 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Topical
• 7.4 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacy
• 8.3 Retail pharmacy
• 8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Assertio Therapeutics
• 10.2 Biogen
• 10.3 Cipla
• 10.4 Dr. Reddy’s Laboratories
• 10.5 Eli Lilly and Company
• 10.6 GlaxoSmithKline
• 10.7 Glenmark Pharmaceuticals
• 10.8 Grunenthal
• 10.9 Johnson & Johnson
• 10.10 Mallinckrodt Pharmaceuticals
• 10.11 Novartis
• 10.12 Pfizer
• 10.13 Sun Pharmaceutical Industries
• 10.14 Teva Pharmaceutical Industries
• 10.15 Vertex Pharmaceuticals